Franz-Josef Neumann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2836479/publications.pdf

Version: 2024-02-01

92 papers 31,361 citations

38 h-index 51608 86 g-index

94 all docs

94 docs citations

times ranked

94

22187 citing authors

#	Article	IF	CITATIONS
1	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2018, 39, 119-177.	2.2	7,100
2	2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 87-165.	2.2	4,537
3	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020, 41, 407-477.	2.2	4,210
4	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2010, 31, 2501-2555.	2.2	2,649
5	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39, 213-260.	2.2	2,246
6	Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein Ilb/Illa Inhibitor Tirofiban. New England Journal of Medicine, 2001, 344, 1879-1887.	27.0	1,918
7	Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention. Circulation, 2007, 116, 2923-2932.	1.6	831
8	Comparison of Balloon-Expandable vs Self-expandable Valves in Patients Undergoing Transcatheter Aortic Valve Replacement. JAMA - Journal of the American Medical Association, 2014, 311, 1503.	7.4	580
9	A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents. Journal of the American College of Cardiology, 2012, 59, 2159-2164.	2.8	569
10	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet, The, 2018, 392, 940-949.	13.7	555
11	Fractional Flow Reserve–Guided Multivessel Angioplasty in Myocardial Infarction. New England Journal of Medicine, 2017, 376, 1234-1244.	27.0	549
12	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2019, 381, 1524-1534.	27.0	543
13	Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents. Journal of the American College of Cardiology, 2008, 51, 1925-1934.	2.8	523
14	Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet, The, 2017, 390, 1747-1757.	13.7	443
15	Cardiac Release of Cytokines and Inflammatory Responses in Acute Myocardial Infarction. Circulation, 1995, 92, 748-755.	1.6	410
16	ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. European Heart Journal, 2015, 36, 1252-1263.	2.2	366
17	Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention. Circulation, 2005, 111, 2560-2564.	1.6	363
18	Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. Journal of the American College of Cardiology, 2000, 35, 915-921.	2.8	334

#	Article	IF	CITATIONS
19	â€Ten commandments' for the 2018 ESC/EACTS Guidelines on Myocardial Revascularization. European Heart Journal, 2019, 40, 79-80.	2.2	330
20	Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Circulation, 2012, 125, 1424-1431.	1.6	207
21	Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. European Heart Journal, 2011, 32, 2274-2281.	2.2	162
22	Sirolimus-Eluting Stents for Treatment of Infrapopliteal Arteries Reduce Clinical Event Rate Compared to Bare-Metal Stents. Journal of the American College of Cardiology, 2012, 60, 587-591.	2.8	152
23	Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. European Heart Journal, 2016, 37, 1538.1-1549.	2.2	147
24	Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps. Blood, 2019, 134, 1859-1872.	1.4	113
25	Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial. American Heart Journal, 2018, 200, 44-50.	2.7	111
26	EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. European Heart Journal, 2020, 41, 1839-1851.	2.2	106
27	Two-Year Results after Directional Atherectomy of Infrapopliteal Arteries with the SilverHawk Device. Journal of Endovascular Therapy, 2007, 14, 232-240.	1.5	83
28	ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. European Heart Journal, 2010, 31, 2482-2491.	2.2	82
29	Midterm Results after Atherectomy-assisted Angioplasty of Below-Knee Arteries with Use of the Silverhawk Device. Journal of Vascular and Interventional Radiology, 2004, 15, 1391-1397.	0.5	74
30	Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. European Heart Journal, 2022, 43, 2783-2797.	2.2	74
31	Operator volume and outcome of patients undergoing coronary stent placement. Journal of the American College of Cardiology, 1998, 32, 970-976.	2.8	73
32	The Duration of the Amplified Sinus-P-Wave Identifies Presence of LeftÂAtrial Low Voltage Substrate and Predicts Outcome After Pulmonary VeinÂIsolation in Patients With PersistentÂAtrial Fibrillation. JACC: Clinical Electrophysiology, 2018, 4, 531-543.	3.2	67
33	Culotte stenting vs. TAP stenting for treatment of de-novo coronary bifurcation lesions with the need for side-branch stenting: the Bifurcations Bad Krozingen (BBK) II angiographic trial. European Heart Journal, 2016, 37, 3399-3405.	2.2	62
34	Arterial Lactate in Cardiogenic Shock. JACC: Cardiovascular Interventions, 2020, 13, 2208-2216.	2.9	61
35	Comparison of Immature Platelet Count toÂEstablished Predictors of PlateletÂReactivity During ThienopyridineÂTherapy. Journal of the American College of Cardiology, 2016, 68, 286-293.	2.8	57
36	Stent Placement vs. Balloon Angioplasty for Popliteal Artery Treatment. Journal of Endovascular Therapy, 2015, 22, 22-27.	1.5	46

#	Article	IF	Citations
37	Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes. Annals of Internal Medicine, 2020, 173, 436-444.	3.9	44
38	Ticagrelor or Prasugrel in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2020, 76, 2436-2446.	2.8	41
39	The Transcription Factor ETV1 Induces Atrial Remodeling and Arrhythmia. Circulation Research, 2018, 123, 550-563.	4.5	40
40	Ultrastructural, transcriptional, and functional differences between human reticulated and nonâ€reticulated platelets. Journal of Thrombosis and Haemostasis, 2020, 18, 2034-2046.	3.8	34
41	Amplified sinus-P-wave reveals localization and extent of left atrial low-voltage substrate: implications for arrhythmia freedom following pulmonary vein isolation. Europace, 2020, 22, 240-249.	1.7	30
42	Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients TreatedÂWith Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2017, 10, 1607-1617.	2.9	29
43	Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk. Circulation, 2020, 141, 891-901.	1.6	28
44	The Natural History of Nonculprit LesionsÂin STEMI. JACC: Cardiovascular Interventions, 2020, 13, 954-961.	2.9	27
45	Ticagrelor or Prasugrel in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation, 2020, 142, 2329-2337.	1.6	26
46	Fractional flow reserve-guided multivessel angioplasty in myocardial infarction: three-year follow-up with cost benefit analysis of the Compare-Acute trial. EuroIntervention, 2020, 16, 225-232.	3.2	24
47	Comparison of various late gadolinium enhancement magnetic resonance imaging methods with high-definition voltage and activation mapping for detection of atrial cardiomyopathy. Europace, 2022, 24, 1102-1111.	1.7	24
48	Culprit lesion location and outcome in patients with cardiogenic shock complicating myocardial infarction: a substudy of the IABP-SHOCK II-trial. Clinical Research in Cardiology, 2016, 105, 1030-1041.	3.3	22
49	Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and PlateletÂReactivity. JACC: Cardiovascular Interventions, 2021, 14, 417-427.	2.9	19
50	Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: Platelet reactivity in an observational study. Platelets, 2013, 24, 549-553.	2.3	16
51	Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis. International Journal of Cardiology, 2018, 252, 57-62.	1.7	16
52	Atherectomy and Drug-Coated Balloon Angioplasty for the Treatment of Long Infrapopliteal Lesions: A Randomized Controlled Trial. Circulation: Cardiovascular Interventions, 2021, 14, e010280.	3.9	16
53	Clinical outcome after percutaneous treatment of de novo coronary bifurcation lesions using first or second generation of drug-eluting stents. Clinical Research in Cardiology, 2016, 105, 230-238.	3.3	15
54	5‥ear outcomesÂafter transcatheter aortic valve implantation: Focus on paravalvular leakage assessed by echocardiography and hemodynamic parameters. Catheterization and Cardiovascular Interventions, 2022, 99, 1582-1589.	1.7	15

#	Article	lF	CITATIONS
55	Purulent pericarditis and pneumonia caused by Streptococcus equi subsp. zooepidemicus. Journal of Medical Microbiology, 2014, 63, 313-316.	1.8	13
56	Discordant cardiac biomarker levels independently predict outcome in ST-segment elevation myocardial infarction. Clinical Research in Cardiology, 2016, 105, 432-440.	3.3	12
57	A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. Canadian Journal of Cardiology, 2020, 36, 1298-1307.	1.7	12
58	Non-invasive body surface electrocardiographic imaging for diagnosis of atrial cardiomyopathy. Europace, 2021, 23, 2010-2019.	1.7	11
59	Valve Thrombosis after TAVI. European Heart Journal, 2017, 38, 2700-2701.	2.2	9
60	Prognostic value of glomerular function estimated by Cockcroft-Gault creatinine clearance, MDRD-4, CKD-EPI and European Kidney Function Consortium equations in patients with acute coronary syndromes. Clinica Chimica Acta, 2021, 523, 106-113.	1,1	9
61	Electrocardiographic diagnosis of atrial cardiomyopathy to predict atrial contractile dysfunction, thrombogenesis and adverse cardiovascular outcomes. Scientific Reports, 2022, 12, 576.	3.3	9
62	Hemodynamic classification of paravalvular leakage after transcatheter aortic valve implantation compared with angiographic or echocardiographic classification for prediction of $1\hat{a} \in \mathcal{Y}$ are mortality. Catheterization and Cardiovascular Interventions, 2018, 91, E56-E63.	1.7	7
63	Determinants of fibrotic atrial cardiomyopathy in atrial fibrillation. A multicenter observational study of the RETAC (reseau européen de traîtement d'arrhythmies cardiaques)-group. Clinical Research in Cardiology, 2022, 111, 1018-1027.	3.3	7
64	Three-year outcomes of percutaneous coronary intervention with next-generation zotarolimus-eluting stents for de novo coronary bifurcation lesions. Journal of Invasive Cardiology, 2014, 26, 630-8.	0.4	7
65	Uncontrolled Diabetes Mellitus Has No Major Influence on the Platelet Transcriptome. BioMed Research International, 2018, 2018, 1-9.	1.9	6
66	Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents. American Heart Journal, 2018, 205, 77-86.	2.7	6
67	Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity. Journal of Thrombosis and Thrombolysis, 2022, 53, 1-9.	2.1	6
68	Complex Stenting for Complex Lesions. JACC: Cardiovascular Interventions, 2019, 12, 1938-1940.	2.9	4
69	Towards a lesion-specific approach to percutaneous coronary intervention for bifurcation lesions. European Heart Journal, 2020, 41, 2537-2540.	2.2	4
70	Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial. Journal of Atherosclerosis and Thrombosis, 2022, 29, 747-761.	2.0	4
71	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2021, 14, e010565.	3.9	4
72	General Anesthesia or Conscious Sedation for Transfemoral Aortic Valve Replacement with the SAPIEN 3 Transcatheter Heart Valve. International Heart Journal, 2020, 61, 713-719.	1.0	4

#	Article	IF	CITATIONS
73	Impact of high platelet turnover on the platelet transcriptome: Results from platelet RNA-sequencing in patients with sepsis. PLoS ONE, 2022, 17, e0260222.	2.5	4
74	Association of Prolonged Fluoroscopy Time with Procedural Success of Percutaneous Coronary Intervention for Stable Coronary Artery Disease with and without Chronic Total Occlusion. Journal of Clinical Medicine, 2021, 10, 1486.	2.4	3
75	Impact of <scp>highâ€sensitivity</scp> cardiac troponin T on survival and rehospitalization after transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2021, 98, E881-E888.	1.7	3
76	Prognostic value of haemoglobin drop in patients with acute coronary syndromes. European Journal of Clinical Investigation, 2021, 51, e13670.	3.4	3
77	Hypo-attenuated leaflet thickening of transcatheter aortic valves: jeopardy or epiphenomenon?. European Heart Journal, 2017, 38, 1218-1221.	2.2	2
78	Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimusâ€eluting stents. Catheterization and Cardiovascular Interventions, 2021, 98, 1111-1119.	1.7	2
79	Correlation and Relative Prognostic Value of Fractional Flow Reserve and Pd/Pa of Nonculprit Lesions in ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121010796.	3.9	2
80	Prediction of risk for bleeding, myocardial infarction and mortality after percutaneous coronary intervention in patients with acute coronary syndromes. Coronary Artery Disease, 2022, Publish Ahead of Print, .	0.7	2
81	Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial. Clinical Research in Cardiology, 2023, 112, 518-528.	3.3	2
82	Evaluation of mortality following paclitaxel drugâ€coated stent angioplasty of femoropopliteal lesions in real world. Catheterization and Cardiovascular Interventions, 2020, 96, 1306-1314.	1.7	1
83	Accuracy of Carotid Artery Stenosis Quantification with 4-D-Supported 3-D Power-Doppler versus Color-Doppler and 2-D Blood Velocity-Based Duplex Ultrasonography. Ultrasound in Medicine and Biology, 2020, 46, 1082-1091.	1.5	1
84	Efficacy and safety of ticagrelor versus prasugrel in smokers and nonsmokers with acute coronary syndromes. International Journal of Cardiology, 2021, 338, 8-13.	1.7	1
85	Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes. Journal of the American Heart Association, 2021, 10, e021418.	3.7	1
86	Preadmission antiplatelet therapy and treatment effect of ticagrelor versus prasugrel in patients with acute coronary syndromes - a subgroup analysis of the ISAR-REACT 5 trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, , .	3.0	1
87	Reply. Journal of the American College of Cardiology, 2021, 77, 1484.	2.8	O
88	Peripheral Vascular Intervention in Patients With Transcatheter Aortic ValveÂReplacement. JACC: Cardiovascular Interventions, 2021, 14, 2581-2583.	2.9	0
89	Koronare Herzkrankheit: Aktuelle Aspekte der Behandlung. , 0, , .		O
90	Access route and clinical outcomes after ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing invasive treatment strategy. Cardiovascular Revascularization Medicine, 2022, ,	0.8	0

6

#	Article	IF	CITATIONS
91	Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes. Revista Espanola De Cardiologia (English Ed), 2021, , .	0.6	O
92	Impact of the Aortic Geometry on TAVI Prosthesis Positioning Using Self-Expanding Valves. Journal of Clinical Medicine, 2022, 11, 2259.	2.4	0